Literature DB >> 15252277

The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats.

E Zakharova1, A Malyshkin, V Kashkin, O Neznanova, I Sukhotina, W Danysz, A Bespalov.   

Abstract

Several drugs, such as N-methyl-D-aspartate (NMDA) receptor channel blockers (memantine), naltrexone (but not naloxone) and acamprosate, have previously been reported to attenuate the expression of the alcohol deprivation effect, a phenomenon seen as an increase in post-deprivation alcohol consumption. The present study aimed to evaluate the effects of these drugs on the development and expression of the saccharin deprivation effect in adult male Wistar rats. Memantine (13 mg/kg per day) and naltrexone (5 mg/kg, twice daily), but not naloxone (24 mg/kg per day) or acamprosate (200 mg/kg, twice daily), prevented the increase in the consumption of saccharin after a 1-week deprivation from free-choice, unlimited access to saccharin (0.1%, w/v). Taken together with the results of previous studies, these results suggest that naltrexone and memantine attenuate the expression of both the alcohol and saccharin deprivation effects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252277     DOI: 10.1097/01.fbp.0000137213.85321.8e

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  4 in total

Review 1.  Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.

Authors:  Joseph T Coyle
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

2.  Incubation of sucrose craving: effects of reduced training and sucrose pre-loading.

Authors:  Jeffrey W Grimm; Amber M Fyall; Dan P Osincup
Journal:  Physiol Behav       Date:  2004-11-13

3.  The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile.

Authors:  Valentina Vengeliene; Achim Moeller; Marcus W Meinhardt; Patrick M Beardsley; Wolfgang H Sommer; Rainer Spanagel; Anton Bespalov
Journal:  Neuropsychopharmacology       Date:  2015-07-28       Impact factor: 7.853

4.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.